Related Experiment Video

Updated: Jul 1, 2026

A Method to Study the C924T Polymorphism of the Thromboxane A2 Receptor Gene
07:00

A Method to Study the C924T Polymorphism of the Thromboxane A2 Receptor Gene

Published on: April 1, 2019

[Polymorphism of platelet glycoprotein Ibalpha as a genetic predictor of coronary artery disease]

Marlena Culjak Aleksić1, Jasna Mesarić

  • 1Magdalenac--Specijalna bolnica za kardiovaskularnu kirurgiju i kardiologiju, Krapinske Toplice. marlena.culjak@magdalena.hr

Lijecnicki Vjesnik
|September 17, 2008
PubMed

Insights

This study found no significant link between the GPIbalpha145Thr/Met (HPA-2) polymorphism and coronary artery disease (CAD) in Croatian patients. Further research on other platelet glycoprotein polymorphisms and CAD is warranted.

Area of Science:

  • Cardiovascular Genetics
  • Hematology
  • Molecular Biology

Context:

  • Atherosclerosis, a multifactorial disease, involves genetic and environmental factors.
  • Platelet membrane antigen polymorphisms are potential risk factors for coronary artery disease (CAD).
  • Previous studies on platelet polymorphisms and CAD have yielded controversial results.

Purpose:

  • To investigate the frequency of the GPIbalpha145Thr/Met (HPA-2) polymorphism in Croatian patients.
  • To assess the association between this polymorphism and the prevalence of CAD.

Summary:

  • 604 Croatian patients (402 with CAD, 202 controls) were analyzed for the GPIbalpha145Thr/Met (HPA-2) polymorphism.
  • Genotype and allele frequencies did not show a statistically significant difference between CAD patients and controls.
  • No significant association was found between the GPIbalpha145Thr/Met (HPA-2) polymorphism and CAD in this cohort.

Impact:

  • Findings align with studies in Central European populations, suggesting limited role of this specific polymorphism in CAD.
  • Highlights the need for further investigation into other platelet glycoprotein polymorphisms and their relationship with CAD in Croatian populations.

More Related Videos

Coronary Progenitor Cells and Soluble Biomarkers in Cardiovascular Prognosis after Coronary Angioplasty10:03

Coronary Progenitor Cells and Soluble Biomarkers in Cardiovascular Prognosis after Coronary Angioplasty

Published on: January 28, 2020

Related Concept Videos

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors01:20

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Pharmacogenomics: Identification of New Drug Targets01:29

Pharmacogenomics: Identification of New Drug Targets

Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
Structure and Function of Platelets01:18

Structure and Function of Platelets

The cell fragments known as platelets are disc-shaped, with an average diameter of about 3 μm and a thickness of roughly 1 μm. They play a crucial role in the body's vascular clotting system, which also involves plasma proteins, blood cells, and blood vessel tissues.
Platelets are continually replenished, circulating in the bloodstream for 9-12 days before being removed by phagocytes, primarily in the spleen. A microliter of circulating blood contains between 150,000 and 450,000 platelets, with...
Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu01:29

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
Coronary Artery Disease II: Pathophysiology01:26

Coronary Artery Disease II: Pathophysiology

Coronary Artery Disease (CAD) originates from a series of events that impair the function of coronary arteries, the blood vessels responsible for delivering oxygen-rich blood to the heart muscle. The pathophysiology of CAD is closely linked to atherosclerosis, a chronic inflammatory and lipid-driven condition affecting the vascular endothelium.1. Endothelial DamageThe process begins with damage to the vascular endothelium, which serves as a protective barrier between the blood and the vessel...